24 research outputs found
Relationship Between Tumor Vascularity and Vascular Endothelial Growth Factor as Prognostic Factors for Patients with Neuroblastoma
Although the role of angiogenesis in tumor progression and response to treatment is generally well-characterized, for
neuroblastomas clinical data regarding the contribution of angiogenesis and its predictive capacity remain unclear. The
aim of this study was to evaluate whether tumor vascularity in the combination with expression of vascular endothelial
growth factor (VEGF) represent prognostic factors for patients with neuroblastoma. Immunohistochemistry using anti-
-CD34 and anti-VEGF antibodies was used to analyze paraffin-embedded primary tumor tissues from 56 patients diagnosed
with neuroblastoma. Tumor vascularity was estimated by calculating the tumor vascular volume fraction (TVVF),
and VEGF expression was determined using semi-quantitative scoring. Statistical analyses including multivariate analysis
were performed and compared with these two factors. Tumor vascularity had impact on survival of high VEGF expression
neuroblastoma patients. Combination of high VEGF expression and TVVF value 5% was independent predictor
of overall survival (p-value =0.0041, odds ratio (OR) (95%CI)=8.67 (1.99ā37.69) by the Cox proportional hazards
model). This study revealed for the first time a group of extremely high-risk neuroblastoma with both high VEGF expression
and poor vascularity. For these patients reduced rates of survival were observed (37% vs. 92.5%) (p<0.0001). These
patients did not experience a significant improvement following hematopoietic stem cell transplantation, and could be
candidates for receiving novel therapies. These results indicate the importance of the mutual relationship between tumor
vascularity and VEGF, because it gives better insight into the prognosis of patients with neuroblastoma
Psychosocial oncology and some aspects of complex rehabilitation in adults and children with malignant diseases
OsjeÄaji i misli koji se pojavljuju u oboljelih od malignih bolesti tijekom dijagnostike, lijeÄenja i rehabilitacije predstavljaju kompleksno problemsko podruÄje za oboljele, druÅ”tvenu okolinu, kao i za struÄnjake iz raznih disciplina u podruÄju biomedicinskih, humanistiÄkih, druÅ”tvenih i drugih znanosti. NaÄin na koji odrasla osoba ili dijete doživljava prijetnju za vlastitu egzistenciju važan je i u njenom suoÄavanju s bolesti tijekom lijeÄenja i rehabilitacije. Interdisciplinarno podruÄje psihosocijalne onkologije prikazano je i u okviru nekih studijskih programa na raznim sveuÄiliÅ”nim i kliniÄkim institucijama u svijetu kao i okviru kolegija āPsihosocijalna onkologijaā na Edukacijsko-rehabilitacijskom fakultetu SveuÄiliÅ”ta u Zagrebu. Posebice su prikazana neka istraživanja koja su provoÄena tijekom lijeÄenja i rehabilitacije osoba oboljelih od raka dojke, kao i u djece sa solidnim malignim tumorima. Istaknuta je potreba adekvatne sveuÄiliÅ”ne edukacije struÄnjaka u podruÄju rehabilitacijskih znanosti kako bi steÄenim kompetencijama tijekom studija i/ili nakon raznih programa specijalizacije, bili u moguÄnosti pružiti komplementarne oblike psihoemocionalne i psihosocijalne podrÅ”ke oboljelima.The emotions and thoughts that appear in people with malignant diseases during diagnostics, treatment and rehabilitation, represent a complex problem area for the patient, social enviroment, as well as professionals from biomedical, humanities, social and other sciences. The way that an adult or child experiences the threat to itĀ“s own existence is very important when coping with their disease during treatment and rehabilitation. Psychosocial oncology as an interdisciplinary field of study is presented within some study programs at various universities and clinical institutions worldwide and within the course āPsychosocial oncologyā at the Faculty of Education and Rehabilitation Sciences at the University of Zagreb. Some clinical and scientific researches that were conducted during the treatment and rehabilitation of patients with breast cancer, as well as in children with solid malignant tumors are shown. The need for adequate university education of professionals in the field of rehabilitation sciences is emphasized, so they may be abled with their acquired competencies during their studies and/or after various specializations, to provide complementary forms of psychoemotional and psychosocial support to patients
Bol i palijativna medicina ā tempus projekt u Hrvatskoj
Pain and Palliative Medicine Project (PPMP), funded by the TEMPUS programme of the European Union, has been established with a goal of sharing knowledge and experience from countries in which palliative care is already substantially developed to partner countries whose palliative care encountered more problems. Croatia as partner country, has tried to improve national palliative care systems through education of medical and non-medical personnel.
Protocols of collaboration and training courses in pain management and palliative medicine at the Universities of Florence and Lyon, including options of collaboration with some university and clinical institutions in Croatia have been presented.
After their two-year project, the Croatian team has noted significant progress in the fields of education, infrastructure and legislative support for development of palliative care. These results show the need for improving Croatian palliative care system as well as possible solutions for overcoming obstacles derived from nationās traditional views on the treatment of the terminally ill.Bol i palijativna medicina (PPMP) je projekt u okviru TEMPUS programa Europske Unije s ciljem prenoÅ”enja znanja i iskustava zemalja, u kojima je palijativna skrb dobro razvijena, zemljama u kojima je palijativna skrb manje aktivna. Hrvatska, kao zemlja partner, nastoji poboljÅ”ati nacionalni program palijativne skrbi kroz edukaciju medicinskog i ne-medicinskog osoblja.
Prikazani su protokoli suradnje i teÄajeva o boli i palijativnoj medicine na SveuÄiliÅ”tima u Firenci i Lyonu, kao i na nekim sveuÄiliÅ”nim i kliniÄkim institucijama u Hrvatskoj.
Nakon dvogodiÅ”njeg projekta hrvatski tim zabilježio je znaÄajni napredak u poljima edukacije, infrastrukture i zakonske potpore razvoju palijativne skrbi. Ovi rezultati su pokazali potrebu za daljnjim poboljÅ”avanjem hrvatske palijativne skrbi kao i moguÄa rjeÅ”enja za prevladavanje prepreka koje proizlaze iz tradicionalnih pogleda druÅ”tva na skrb terminalno bolesnih
Bol i palijativna medicina ā tempus projekt u Hrvatskoj
Pain and Palliative Medicine Project (PPMP), funded by the TEMPUS programme of the European Union, has been established with a goal of sharing knowledge and experience from countries in which palliative care is already substantially developed to partner countries whose palliative care encountered more problems. Croatia as partner country, has tried to improve national palliative care systems through education of medical and non-medical personnel.
Protocols of collaboration and training courses in pain management and palliative medicine at the Universities of Florence and Lyon, including options of collaboration with some university and clinical institutions in Croatia have been presented.
After their two-year project, the Croatian team has noted significant progress in the fields of education, infrastructure and legislative support for development of palliative care. These results show the need for improving Croatian palliative care system as well as possible solutions for overcoming obstacles derived from nationās traditional views on the treatment of the terminally ill.Bol i palijativna medicina (PPMP) je projekt u okviru TEMPUS programa Europske Unije s ciljem prenoÅ”enja znanja i iskustava zemalja, u kojima je palijativna skrb dobro razvijena, zemljama u kojima je palijativna skrb manje aktivna. Hrvatska, kao zemlja partner, nastoji poboljÅ”ati nacionalni program palijativne skrbi kroz edukaciju medicinskog i ne-medicinskog osoblja.
Prikazani su protokoli suradnje i teÄajeva o boli i palijativnoj medicine na SveuÄiliÅ”tima u Firenci i Lyonu, kao i na nekim sveuÄiliÅ”nim i kliniÄkim institucijama u Hrvatskoj.
Nakon dvogodiÅ”njeg projekta hrvatski tim zabilježio je znaÄajni napredak u poljima edukacije, infrastrukture i zakonske potpore razvoju palijativne skrbi. Ovi rezultati su pokazali potrebu za daljnjim poboljÅ”avanjem hrvatske palijativne skrbi kao i moguÄa rjeÅ”enja za prevladavanje prepreka koje proizlaze iz tradicionalnih pogleda druÅ”tva na skrb terminalno bolesnih
Metastaze u nosnoj Å”upljini, paranazalnim sinusima i nazofarinksu - prikazi sluuÄajeva
Uvod: Metastaze u nosnu Ŕupljinu, paranazalne sinuse i nazofarinks su rijetke, ali ako su prisutne tada
je najÄeÅ”Äe sijelo maksilarni sinus. PrateÄi simptomi metastaze u navedenim sijelima mogu imitirati druga
benigna i ÄeÅ”Äa stanja, a prava etiologija se može predvidjeti i propustiti tijekom duljeg razdoblja.
Prikaz sluÄaja: Prikazujemo dva sluÄaja s prisutnim tumorskim tvorbama u nosnoj Å”upljini,
paranazalnim sinusima i nazofarinksu s razliÄitom kliniÄkom slikom i konaÄnim ishodom. Prvi je sluÄaj
ŔesnaestogodiŔnjeg bolesnika sa suspektnom metastazom ekstraosealnog Ewingovog sarkoma lijeve
potkoljenice u nazofarinks i desni maksilarni sinus. Sumnja je postavljena nakon snimanja PET/CT-a, a
bolesnik nije imao tegobe od strane nosa i paranazalnih Ŕupljina. PatohistoloŔka analiza bioptata ukazala je
na upalne promjene bez tumorskih stanica. Drugi je sluÄaj pedesetsedmogodiÅ”nje bolesnice koja se žalila
na otežano disanje i uÄestale epistakse iz lijeve nosnice. KliniÄkim pregledom i radioloÅ”kom obradom bila
je vidljiva tumorska tvorba u lijevom nosnom kavumu, a patohistoloŔka analiza bioptata ukazala je na
metastazu karcinoma bubrega.
ZakljuÄak: Metastaze u nosnu Å”upljinu, paranazalne sinuse i nazofarinks vrlo su rijetke. MoguÄi je Å”irok
spektar prateÄih simptoma, a njihova odsutnost ne iskljuÄuje moguÄnost prisutnosti metastaze. Svaki
patoloÅ”ki nalaz utvrÄen kliniÄkim pregledom ili radioloÅ”kom obradom, te prisutnost tegoba od strane nosa
i paranazalnih sinusa kod bolesnika s malignom boleÅ”Äu zahtjeva pregled i obradu otorinolaringologa
Central Venous Catheters for Chemotherapy of Solid Tumors ā Our Results in the Last 5 Years
Central venous catheters provide an easy access for intravenous medications. Having a central line in place will relieve
a child from the discomfort and danger of multiple regular intravenous lines for chemotherapy. The use of indwelling
central venous catheters has become commonplace in the management of children undergoing oncological treatment.
There are two types of central lines commonly used. There are Broviac catheters and Port-A-Cath (PAC) catheters. In the
last 5 years we inserted 194 catheters in 175 children. We inserted 121 Broviac catheters and 73 PAC catheters. During
the follow up of 39382 catheter days 44 complications were observed. In Broviac group the median follow up was 155
days and in PAC group was 230 days. We observed differences in the incidence between two devices. In Broviac group infections
were more frequent and in PAC group other complications were more frequent than infections
PlaÄ bez glasa. Laringealna papilomatoza u djece (RRP) - mijenja li se pristup lijeÄenju?
Rad prikazuje novi pristup u lijeÄenju rekurirajuÄe respiratorne papilomatoze (RRP). LijeÄenje djeÄje
rekurentne respiratorne papilomatoze i dalje ukljuÄuje uÄestale i agresivne operacijske postupke, kako bi se
postigla prohodnost diÅ”nih putova i osigurala kvaliteta glasa. Tim naÄinom lijeÄenja naruÅ”ava se kvaliteta
života djece, a nerijetko postoji potreba za hitnim operacijskim zahvatima, pa Äak i privremenom
traheotomijom zbog stridoroznog disanja i respiracijske insuficijencije. Kako bi se broj operacijskih zahvata
smanjio na minimum, istraživana je lokalna primjena lijekova adjuvantno u papilomatozne lezije respiratorne
sluznice. TakoÄer, cijepljenjem protiv HPV-a postižu se rezultati u sprjeÄavanju ove bolesti. NajÄeÅ”Äe koriÅ”teni
lijekovi u lijeÄenju RRP su cidofovir i bevacizumab. U posljednjih desetak godina, postoje studije koje daju
nadu u uÄinak bevacizumaba primijenjenog lokalno i sustavno. Sustavna primjena rezervirana je za bolesnike
koji trebaju viŔe od 4 operacije godiŔnje, koji imaju brzi recidiv bolesti s opstrukcijom diŔnih putova, te imaju
distalno Ŕirenje bolesti. Bevacizumab je monoklonsko protutijelo koje se selektivno veže na krvožilni endotelni
faktor rasta (VEGF), a registriran je za sistemsku primjenu unutar indikacijskih okvira koji, za sada, ne
ukljuÄuju rekurentnu respiratornu papilomatozu. Na temelju znanstvene literature koja aktualno istražuje
djelovanje sistemski primijenjenog bevacizumaba u rekurentnoj respiratornoj papilomatozi, prikazujemo
sluÄaj uspjeÅ”nog kombiniranog kirurÅ”kog i adjuvantnog lijeÄenja bolesti u djeteta Äiji je tretman zapoÄet u dobi
od 18 mjeseci